Sector News

Top U.S. execs flee Ranbaxy as Sun Pharma merger looms: paper

October 13, 2014
Life sciences
Ranbaxy Laboratories has been a steady source of bad news over the past several years. And now that India-based rival Sun Pharmaceuticals is preparing to take over, the company’s top U.S. leadership is throwing in the towel.
 
According to the Indian newspaper, Business Standard, up to a half-dozen of the company’s U.S. execs are headed for the door, with country chief Venkatachalam Krishnan among them. Citing unnamed sources, the paper says department heads in finance, legal, sales and distribution have also turned in their resignations.
 
Sun Pharma agreed to buy Ranbaxy in April in a $4 billion deal and awaits regulatory approval for closing the deal. As the buyout was announced, sources started chattering that Sun would phase out the Ranbaxy brand in the U.S. Sun was also said to be planning to oust plant managers who had presided over serious manufacturing violations that landed Ranbaxy in hot water repeatedly since 2009.
 
It’s clear that Sun will have its hands full dealing with Ranbaxy’s checkered regulatory history. Four facilities are operating under a consent decree with the FDA, and the Department of Justice has issued a subpoena for information on a plant in Toansa, India, previously banned by the FDA. Sun will also have to deal with at least one state government investigation into Ranbaxy’s potential Medicaid overcharges.
 
Meanwhile, Sun has racked up its own series of recalls since announcing it would buy Ranbaxy. The company had announced three recalls by June, and an FDA warning letter chided Sun for dirty facilities, data-manipulation problems, and lax quality control, similar to the infractions that snagged Ranbaxy.
 
This wouldn’t be the first exodus from Ranbaxy in recent months. As the Business Standard points out, global quality chief Dale Adkisson and global HR head Sandeep Girotra said their goodbyes recently.
 
By Tracy Staton
 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).